Effects of Low-Dose Spironolactone Combined with Metformin or Either Drug Alone on Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Pilot Study

Table 4

Compliance among the three groups during 12 weeks of treatment.

	MET group (n = 54)	SPI group (n = 53)	COM group (n = 51)
Nausea	6 (11.1%)	3 (5.88%)	5 (9.43%)
Diarrhea	3 (1.67%)	2 (3.92%)	3 (5.66%)
Vomiting	1 (1.85%)	0	1 (1.89%)
Polyuria	0	1 (1.96%)	0
Dry mouth	0	2 (3.92%)	0

MET: metformin; SPI: spironolactone; COM: combined.